Therapeutic Potential of Ibuprofen Inhalation for COVID-19 Pneumonia: Report of Two First Cases

German Ambasch1, Esteban Coscia1, Jorge Luis Tambini Diaz1, German David Bueno1, Luis Alberto Arganaras2, Nicolas Martinez Rios3, Daniela Josefina Porta3, Dante Miguel Beltramo4 and Nestor Horacio Garcia5*

1Sanatorio Mayo Privado SA, Ciudad de Córdoba, Argentina  
2Quimica Luar SRL, Ciudad de Córdoba, Argentina  
3CEPROCOR, Santa María de Punilla, Argentina  
4CONICET, Santa María de Punilla, Argentina  
5Institute for Research in Health Sciences, Ciudad Universitaria, Argentina

Abstract

No specific and effective antiviral treatment has been approved for COVID-19 so far. Systemic corticosteroid and remdesivir have shown to decrease mortality in COVID-19 patients, but mortality still is elevated. We propose that nebulized hypertonic ibuprofen solution which has bactericidal, virucidal, mucolytic and anti-inflammatory properties to be used for COVID-19 pneumonia and prevent the classical evolution to respiratory failure and mechanical respiration. We report here the first two cases of the COVID-19 pneumonia successfully treated with Nebulized Hypertonic Ibuprofen Solution (NaIHS). Rationale of the treatment is to mitigate the local inflammation with inhaled NIH that stays in the lung and may inhibit proliferation of the virus, inflammation and successfully reverts the hypoxia observed in these clinical cases. Mild adverse events were observed. Larger and further studies are warranted to confirm the result of these cases.

Keywords: Hypertonic ibuprofen solution; Inhalation; Coronavirus disease 2019

Abbreviations

COVID-19: Coronavirus Disease 2019; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus

Introduction

Disease due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19, has taken the world by storm. More than 201 million cases and greater than 4 million deaths have been reported by the World Health Organization [1] and effective therapy options remain limited. To date, dexamethasone, remdesivir, tofacitinib, and monoclonal antibody therapies have demonstrated benefit in patients with severe illness [2], while evidence of benefit for many other drugs remains unknown [3] or disproven [4-7].

A classical presentation of severe COVID-19 is profound hypoxia, progressing to Acute Respiratory Distress Syndrome (ARDS). Pulmonary release of autacoids leading to vascular injury and permeability results in excess alveolar fluid protein accumulation. This phenomenon, coupled with vasodilation and intrapulmonary shunting of non-oxygenated blood has been characterized as a ‘bradykinin storm’ [8]. This mismatch contributes to ventilation/perfusion mismatch and the consequence of hypoxia. Importantly, ibuprofen can prevent inflammation induced by bradykinin at the respiratory mucosa [9] and it has also been demonstrated to prevent bradykinin induced vascular extravasation and angioedema in humans [10]. These data suggest that ibuprofen may mitigate this aspect of the inflammatory response in COVID-19.

Previously we hypothesized that nebulized hypertonic ibuprofen has antibiotic, viricidal and anti-inflammatory effects that are expected to prevent viral replication in the respiratory tract, minimize bacterial super infections and reduce inflammatory cytokines which appear to be the major problems in COVID-19 [11]. Ibuprofen with the highest FDA performance side effect profile had showed to be safe given orally or ev, and can be given at any age. Based on that ethical approval was obtained from the Institutional Independent Ethics Committees and district regulatory agencies...
of Córdoba Province on April 4th, 2020, for the compassionate use of Luarprofeno® (sodium ibuprofenate in hypertonic saline for nebulization) (hereafter, NaIHS).

The 2 patients were hospitalized by April, 2020 had physical symptoms and radiological findings of pneumonia. The possible efficacy of NaIHS (Trade name: Luarptofen®) was evaluated. These 2 patients with poor oxygenation and radiologic signs of COVID-19 pneumonia revert rapidly. In these cases, clinical courses revealed favorable.

**Case Series**

**Case 1: Female, 77 years old**

She was admitted on April 20th, 2020 due to sore throat, malaise, loss of appetite, and dyspnea without fever derived from a home care center from Villa Saldán, Córdoba suspecting COVID-19 pneumonia, the patient had a positive throat swab PCR test on April 18th, 2020 for SARS-CoV-2. Past history: Hypertension, Dyslipidemia. Physical findings: No pharyngeal redness, no lymphadenopathy, rhonchus, wheezes and fine crackles could be heard in both lung fields at the end of inspiration. Rest of the examination was normal. Blood pressure 140/60 mmHg, pulse rate 85/min, respiratory rate 23/min, body temperature 36.5°C, SpO2 86%/RA. EKG with left atrial overload. Laboratory findings were listed in Table 1. Chest X-ray on admission revealed mild infiltration shadow in lower right lung field (Figure 1) and chest CT on the same day demonstrated Ground-Glass Opacities (GGO) along the pleura over both middle and lower lung fields (Figure 2). Based on these findings, oxygen supplementation (4 L/min), enoxaparin 40 mg sc, bid, ceftriaxone 1gr ev bid, clarithromycin 500 mg ev bid and respiratory kinesiotherapy were started.

The clinical course is illustrated in Figure 3. On admission, she started with oxygen 4 L/min nasal but SpO2 increase slightly and it did not reach 92%. She felt fatigue, lying down almost all the time, and could hardly take any food. There was poor communication and disorientation. After 24 h of admission, oxygen supplementation at 4 L/min was required but SpO2 was not ≥95%, and 50 mg NaIHS was started each 8 h. Oxygenation gradually improved, and after the 24 h, SpO2 was 94%. Each dose was administered using a high flow oxygen by face-mask. To reduce health care worker infection risk in the setting of nebulized therapy use, a novel containment hood was utilized with air venting via antiviral filters, designed to prevent particle aerosolization. All health care workers utilized Personal Protective Equipment (PPE) provided. Each nebulized dose was administered over approximately 15 min, the time required to drain the liquid nebulization vessel. Fever was never present. After the start NaIHS oxygenation improved, respiratory rate decreased progressively every day.

Within 24 h to 48 h after starting NaIHS, there was no body temperature above 36.5°C, oxygenation had improved. SpO2 was maintained at ≥94% with less O2 requirements and after the 4th day of NaIHS SpO2 was maintained at ≥94% with RA. Hypoxemia during bodily movement also improved. NaIHS was very good tolerated, but it induced during the first nebulization, mild cough, but after the first 5 min, it was minimal. Her appetite remarkably recovered, her fatigue improved, and she became able to walk indoors without any aid. The patient was judged to have improvement from COVID-19. By the 10th day, the patient was ready to be discharge home care. Nasal swab PCR tests was negative for SARS-CoV-2 but she was discharged on May 20th, 2020 due to social difficulties.

**Table 1:** Results of laboratory tests conducted on the day of admission (Case 1).

<table>
<thead>
<tr>
<th>Hematology</th>
<th>Biochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (µL)</td>
<td>Glucose (mg/dl)</td>
</tr>
<tr>
<td>4260</td>
<td>107</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>Urea (mg/dl)</td>
</tr>
<tr>
<td>65%</td>
<td>46</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>Creatinine (mg/dl)</td>
</tr>
<tr>
<td>30%</td>
<td>0.84</td>
</tr>
<tr>
<td>Monocytes (%)</td>
<td>Total Bilirubin (mg/dl)</td>
</tr>
<tr>
<td>4%</td>
<td>4.5</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>AST (U/L)</td>
</tr>
<tr>
<td>1%</td>
<td>38</td>
</tr>
<tr>
<td>Basophils (%)</td>
<td>ALT (U/L)</td>
</tr>
<tr>
<td>0%</td>
<td>30</td>
</tr>
<tr>
<td>Red Blood Cells (106/µL)</td>
<td>LDH (U/L)</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>ALP (U/P)</td>
</tr>
<tr>
<td>11.4</td>
<td>450</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>Sodium (mEq/L)</td>
</tr>
<tr>
<td>35.6</td>
<td>134</td>
</tr>
<tr>
<td>Platelets (103/µL)</td>
<td>Potassium (mEq/L)</td>
</tr>
<tr>
<td>110</td>
<td>3.2</td>
</tr>
<tr>
<td>D-dimer (ng/ml)</td>
<td>Chloride (mEq/L)</td>
</tr>
<tr>
<td>1464</td>
<td>102</td>
</tr>
<tr>
<td>Ferritin (mcg/l)</td>
<td></td>
</tr>
<tr>
<td>792</td>
<td></td>
</tr>
</tbody>
</table>

**Case 2: Male, 59 years old**

This 59 years old man was brought by the emergency service because of dry cough, fatigue, respiratory difficulties having a recent throat swab PCR positive. A fever of 38.4°C was noted. Status at the first consultation: Alert and conscious, but marked fatigue, blood pressure 126/80 mmHg, pulse 93/min, respiratory rate 32/min, body...
Nestor Horacio Garcia, et al.,
temperature 38.0°C, SpO2 91%/RA. Physical findings: No pharyngeal redness, no lymphadenopathy, no edemas, but he presented respiratory distress findings (dyspnea, intercostal retraction, cyanosis etc.) associated to crackles, wheezes and stridor. Past history: Hypertension, no smoking history. Laboratory findings were listed in Table 2. Chest X-ray on admission showed bilateral infiltrative shadow in lower lung fields. Chest CT on the same day documented typical appearance of COVID-19 with bilateral and extensive GGO and lobe consolidation in both lung fields (Right = Left) (Figure 4A, 4B). Initially the patient received enoxaparin 40 mg sc, bid, ceftriaxone 1 g ev bid, clarithromycin 500 mg ev bid, and respiratory kinesiotherapy. Post-admission progress: The clinical course is illustrated in Figure 4. His body temperature on admission was 38.0°C, but then fluctuate between 37.2°C and 36.0°C. Oxygen saturation on admission was 91% to 88% with nasal O2 4 L/min, after 24 h, NaIHS was suggested to the patient. NaIHS was administered during 15 min using a high flow oxygen by face-mask at 6 L/min, health care worker utilized PPE.

Figure 5 shows the SpO2 along the hospitalization during NaIHS treatment, oxygen saturation initially was maintained in normal values with nasal prolongs at 3 L, 4 L, high flow oxygen by face-mask and after 6 days of treatment, no oxygen supplementation was required to maintain SpO2 ≥94%. NaIHS was given during 7 days 50 mg via nebulization tid. His appetite gradually improved, and after 7 days of treatment, oxygen was stopped, fatigue was improved and the patient tolerate walking without fatigue, desaturation occurred and it was associated to the presence of remanent wheezes until he was discharged (Day 14). A pharyngeal swab PCR was performed and the patient was ready for discharge.

Discussion
This report describes clinical outcomes in 2 cases of mild to moderate-stage COVID-19 with NaIHS, inhaled hypertonic ibuprofen, and obtained favorable results under a compassionate use program. The first described patient came to our institution after an intense spread of the virus in a home care setting of geriatric population. All these patients had poor oxygenation and pneumonia showing ground-glass shadow on chest CT. In our case, the course of multiple critical patient outcome parameters (NEWS2 Scores, RR and SpO2) improved rapidly following the initiation of NaIHS. Once admitted, it was clear in these patients, that respiratory failure was progressive, since SpO2 did not improve during the first 24 h associates, as expected with an increase of respiratory rate. Once NaIHS was initiated, a rapid increase of SpO2 was observed but to maintained this oxygen improvement, NaIHS was given 3 times a day. By Day-6 to 8 following initiation of therapy, mean NEWS2 scores improved to <4, pulse oximetry had improved to ≥ 94% with diminishing supplemental oxygen needs, and respiratory rates had returned to normal. This presentation is different than the classical COVD-19 pneumonia, which became rather serious, and as noted in many reports, it worsens rapidly 7 to 10 days after onset. These were impressive cases.

Today it is clear that inflammation is the hallmark of COVID-19 lung injury induced by viral infection, and it is expected that the antiviral and anti-inflammatory effects of NaIHS will be effective in treating lung injury caused by coronavirus, which is becoming
Figure 4: Images in a 49-year-old man who presented with fever and COVID-19 pneumonia. A, B) Thin-slice (1-mm) axial CT images showed multiple patchy ground-glass opacity along the peribronchial and subpleural lungs. Some reticular opacities were also found within areas of ground glass (crazy-paving pattern).

Figure 5: A clinical course of case 2. Solid line represents SpO2, dash dotted line represents Respiratory rate, dotted line represents body temperature.

more severe. The pulmonary delivery of NaIHS diminished bradykinin-storm physiology, likely reduced local prostaglandin and thromboxane synthesis and acutely improved the ventilation-perfusion mismatch which is a stamp of this disease.

Ibuprofen is not commercialized as inhaled drug in Argentina, but, due to the pandemic, health authorities approved the compassionate use of some drugs. At that moment, our preclinical data provided information to speculate that ibuprofen continues to be safe even via nebulization. We tested the safety of higher doses in animals during 1 h nebulization period during 4 months and no significant histological changes were observed in rat lungs. Additionally, in humans' serum ibuprofen increased from 0 to 1.09 ± 0.7 μg/ml and also the reactive oxygen species decreased from 1043 ± 252 to 441 ± 48 AU determined 30 min after the nebulization, demonstrating in spite of the low serum concentration, this presentation still maintains the anti-inflammatory property. Finally, this beneficial effect induced by ibuprofen via nebulization in lung diseases was also observed with other NSAIDs such as indomethacin evaluating the control of bronchiectasis severity, other pulmonary disease are under investigation. The adverse events induced by NaIHS were mild in these two patients. Only mild cough during the first nebulization. After 24 h, these two patients tolerated very well NaIHS, suggesting that ibuprofen via nebulization maintains the excellent safety profile observed previously.

Today, more than 15,000 patients were treated with NaIHS via a Compassionate Program in Argentina, a report will be available soon and based on these results a Phase II trial was authorized by the National Regulatory Authority (ANMAT #Expte 1-0047-0002-000699-20-9; Pegasus) hoping to end by the end of the year.

Conclusion

Two cases of pneumonia COVID-19 with rapid reverse of hypoxia, complete recovery and excellence tolerance after NaIHS administration. After 7 to 10 days of treatment, hypoxia was recovered rapidly. These beneficial effects must be confirmed with the Phase 2 protocol, Pegasus, since early administration of NaIHS is safe, simple and inexpensive.

Authorship Statement

Prof. Dr. German Ambasch and his team treated all the patients. Dr. Néstor H. García contributed to design the protocol treatment for the patients based on the basic and clinical information about NaIHS. All other authors have contributed with the writing, editing and critically reviewed the manuscript.

All authors approved the final version of the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors meet the
References


